A company on a mission
Pivot is a leading digital health company aiming to to engage and empower millions of people to quit all forms of tobacco.
Pivot is a leading digital health company aiming to to engage and empower millions of people to quit all forms of tobacco.
Pivot began with a mission: to help reduce preventable deaths. By empowering people to quit tobacco or vape, we are improving people’s wellness - our ultimate goal.
We’re lucky to be joined on this journey by some of the best investors in the game.
Dr. Utley graduated from Harvard Medical School (’92) and completed his surgical training in otolaryngology-head and neck surgery, as well as facial plastic and reconstructive surgery, at Stanford University Medical Center, where he was subsequently appointed to the faculty as clinical assistant professor of surgery (1992-2003). He has over 25 peer-reviewed publications related to GI, plastic and reconstructive surgery, and otolaryngology.
Prior to starting Carrot, Utley was the first employee and Chief Medical Officer for BARRX Medical (GI endoscopy, acquired by Covidien in 2012) from 2003 to 2014.
Utley has had additional roles as founder, chief medical officer, or member of the board of directors with several start-up medical device companies, including: Somnus Medical Technologies (ENT), Curon Medical (GI), Aetherworks (pulmonary), BAROnova (GI), Freedom-2 (plastics), and CoAlign Innovations (spine), and is the inventor on more than 65 issued U.S. patents and 100 published U.S. patents.
Dan is a seasoned executive with over 30 years of medical device experience, who has worked in small entrepreneurial companies, as well as Fortune 500 corporations.
Dan recently held C-level positions at DFINE, Inc. as Chief Development Officer until it’s acquisition in July of 2016 and prior to DFINE, as the President & CEO, and member of the Board of Directors, of BaroSense, Inc., a company focused on minimally invasive devices for the treatment of obesity.
Early in his career Dan held various senior management and engineering roles at Rita Medical (successful IPO in August 2000), Johnsons & Johnson Medical Inc., VA (as world-wide Director of R&D), Menlo Care (acquired by J&J in May of 1995) and American Pharmaseal.
Dan currently sits on the Board of Directors for BAROnova, a clinical-stage medical-technology company developing endoscopically-delivered devices for the chronic treatment of obesity.
Dan holds a BSME from California Polytechnic State University and is the author of over 120 patents or patent applications in the medical device field.
Ha Van T. Le has more than 20 years of experience in budgeting, finance, and accounting for the high-tech industry, with an emphasis in business enterprise solutions and business intelligence.
Throughout her career, Ha Van has participated in multiple acquisitions and two successful initial public offerings: Accuray, Inc. in 2007 and Valicert, Inc. in 2000.
In 2003, Valicert merged with Tumbleweed Communications (NASDAQ: TMWD).
Prior to joining Carrot, Ha Van was the Corporate Controller and VP, Finance and Revenue Operations, at GetInsured, where she played an integral role in the company’s success and growth from 10 to 450 employees.
Ha Van joined Carrot in November of 2017, bringing an in-depth and a wide array of experience and expertise in Finance Operations. As Carrot’s Senior Director, Finance, she is responsible for all aspects of the company’s financial management.
Ha Van holds an MBA from San Jose State University of California and a BS in Managerial Economics from the University of California, Davis.
Dr. Marler received her BS in Neuroscience from UCLA, graduated from the Medical College of Virginia and trained in Radiology at the University of Virginia.
Prior to joining Carrot, she served as the Sr. Director of Global Medical Affairs for BARRX Medical (GI endoscopy, acquired by Covidien in 2012) from 2008 to 2015.
She had increasing roles of responsibility while at BARRX Medical and Covidien, ultimately managing the Medical Affairs team with oversight of the clinical evidence-based strategy, peer relationships, clinical education, and medical writing along with collaborative leadership in clinical trial design, reimbursement and regulatory strategy.